{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T22:42:38Z","timestamp":1776465758044,"version":"3.51.2"},"reference-count":26,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>There is emerging evidence suggesting a possible association between glucagon-like peptide-1 receptor agonists (GLP-1 RA) and non-arteritic anterior ischemic optic neuropathy (NAION). Retrospective cohort studies supporting this association report hazard ratios ranging from 2.19 to 7.74 when comparing exposed vs unexposed groups. This article explores the current research surrounding the risk of NAION with GLP-1 RA use in patients with type 2 diabetes and obesity, analyses patient factors that may increase susceptibility and highlights key areas warranting further research to guide endocrinologists in future prescribing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Whilst the emerging evidence suggests a possible association between commencement of GLP-1 RAs and NAION, absolute risk remains low and needs to be balanced with the known substantial benefits of GLP-1 RAs. Further research is needed to investigate whether specific patient characteristics such as optic disc parameters, blood pressure changes, degree of weight loss, or improvement of glycemic control can assist clinicians in identifying those at higher risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf541","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:30:26Z","timestamp":1759145426000},"page":"e308-e313","source":"Crossref","is-referenced-by-count":2,"title":["GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischemic Optic Neuropathy: What an Endocrinologist Needs to Know"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7034-1635","authenticated-orcid":false,"given":"Livia","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Concord Repatriation General Hospital , Sydney 2137 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharanya","family":"Mohan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Concord Repatriation General Hospital , Sydney 2137 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Concord Repatriation General Hospital , Sydney 2137 ,","place":["Australia"]},{"name":"Department of Diabetes and Endocrinology, Royal North Shore Hospital , Sydney 2065 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of Sydney , Sydney 2006 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"3","key":"2025121807433284900_dgaf541-B1","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"issue":"24","key":"2025121807433284900_dgaf541-B2","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025121807433284900_dgaf541-B3","author":"World Health Organisation"},{"key":"2025121807433284900_dgaf541-B4","author":"European Medicines Agency"},{"issue":"06","key":"2025121807433284900_dgaf541-B5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.5664\/jcsm.2766","article-title":"Obstructive sleep apnea and nonarteritic anterior ischemic optic neuropathy: evidence for an association","volume":"9","author":"Archer","year":"2013","journal-title":"J Clin Sleep Med"},{"issue":"8","key":"2025121807433284900_dgaf541-B6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jocn.2009.04.002","article-title":"Non-arteritic anterior ischaemic optic neuropathy: a review and update","volume":"16","author":"Kerr","year":"2009","journal-title":"J Clin Neurosci"},{"issue":"21","key":"2025121807433284900_dgaf541-B7","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"2025121807433284900_dgaf541-B8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-8587(17)30109-2","article-title":"Semaglutide, lipid-lowering drugs, and NAFLD","volume":"5","author":"Katsiki","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2025121807433284900_dgaf541-B9","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1111\/dom.13339","article-title":"Glucagon-like peptide-1 receptor expression in the human eye","volume":"20","author":"Hebsgaard","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2025121807433284900_dgaf541-B10","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"2025121807433284900_dgaf541-B11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int J Retina Vitreous"},{"issue":"6","key":"2025121807433284900_dgaf541-B12","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study","volume":"27","author":"Simonsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2025121807433284900_dgaf541-B13","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"143","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"2025121807433284900_dgaf541-B14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/01658107.2024.2411260","article-title":"Bilateral non-arteritic anterior ischemic optic neuropathy following weight loss from semaglutide (ozempic): a case report","volume":"49","author":"Karam","year":"2025","journal-title":"Neuro-Ophthalmol"},{"issue":"1","key":"2025121807433284900_dgaf541-B15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.33696\/cardiology.6.068","article-title":"Semaglutide-inducing non-arteritic anterior ischemic optic neuropathy and ipsilateral blindness -A rare presentation","volume":"6","author":"Mao","year":"2025","journal-title":"J Clin Cardiol"},{"issue":"1","key":"2025121807433284900_dgaf541-B16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12886-025-03958-4","article-title":"Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association","volume":"25","author":"Ahmadi","year":"2025","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"2025121807433284900_dgaf541-B17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaophthalmol.2024.6058","article-title":"Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide","volume":"143","author":"Katz","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"2025121807433284900_dgaf541-B18","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/dom.16076","article-title":"Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: a meta-analysis of randomised controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2025121807433284900_dgaf541-B19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/jamaophthalmol.2025.0349","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes","volume":"143","author":"Hsu","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"2025121807433284900_dgaf541-B20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"key":"2025121807433284900_dgaf541-B21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy","volume":"274","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"2025121807433284900_dgaf541-B22","doi-asserted-by":"crossref","first-page":"e0313098","DOI":"10.1371\/journal.pone.0313098","article-title":"Hypoperfusion states could increase the risk of non-arteritic anterior ischemic optic neuropathy","volume":"19","author":"Gabbay","year":"2024","journal-title":"PLoS One"},{"issue":"19","key":"2025121807433284900_dgaf541-B23","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso Steven","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2025121807433284900_dgaf541-B24","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaneurol.2025.2020","article-title":"GLP-1 Receptor agonists in idiopathic intracranial hypertension","volume":"82","author":"Sioutas","year":"2","journal-title":"JAMA Neurol"},{"issue":"11","key":"2025121807433284900_dgaf541-B25","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ophtha.2010.03.006","article-title":"Bilateral diabetic papillopathy and metabolic control","volume":"117","author":"Ostri","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"2025121807433284900_dgaf541-B26","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s11033-025-10490-7","article-title":"Diabetic retinopathy: a comprehensive review of pathophysiology and emerging treatments","volume":"52","author":"Shyam","year":"2025","journal-title":"Mol Biol Rep"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf541\/64429953\/dgaf541.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/1\/e308\/64429953\/dgaf541.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/1\/e308\/64429953\/dgaf541.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:45:09Z","timestamp":1766061909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/1\/e308\/8268255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,30]]},"published-print":{"date-parts":[[2025,12,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf541","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,30]]}}}